Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Golgin A6 family like 24 (GOLGA6L24) is annotated as a member of the golgin A6 protein family; however, it is primarily classified as a *pseudogene* (sometimes specifically listed as "GOLGA6L24P") and does not encode a confirmed functional protein in humans[1][8]. Pseudogenes are genomic DNA sequences similar to normal genes but are generally non-functional due to mutations or lack of regulatory elements[2][4]. There are no direct links to therapeutic drug targeting, biomarker applications, or documented physiological or disease roles for GOLGA6L24 specifically. No interacting drugs, mechanisms of action, or safety considerations have been reported for this pseudogene. While some pseudogenes can have regulatory functions at the RNA level (such as acting as microRNA decoys or regulators of gene expression), there is no specific evidence for such roles for GOLGA6L24[4][6].\n\nSummary: GOLGA6L24 is a pseudogene in the human genome tied to the golgin family but is not a functional receptor, enzyme, or drug target. Its primary significance is in genomic annotation rather than therapeutic relevance[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Golgin A6 family like 24 (GOLGA6L24).